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Abstract The purpose of this study was to evaluate the
feasibility and efficacy of a treatment concept combining
three cycles of full-dose chemotherapy (CT) with concomi-
tant accelerated uninterrupted radiotherapy (RT). Twenty-
three patients (median age: 54 years, range: 35–70) with
locally advanced squamous cell carcinoma of the head
and neck (SCCHN) were included. The primary tumor in-
volved the hypopharynx (n=7), base of the tongue (n=10),
nasopharynx (n=2) or upper esophagus (n=1) or its loca-
tion was unknown (n=3). Treatment consisted of three cy-
cles of chemotherapy (cisplatin 100 mg/m2 on day 1; 5-FU
1,000 mg/m2 per day for 5 days as a continuous infusion,
preceded by amifostine 910 mg/m2), repeated every 3 weeks.
Uninterrupted concomitant boost-accelerated RT (total
dose of 70 Gy in 6 weeks) started together on day 1 of the
second cycle. All but two patients received the full course
of RT. Eighteen patients achieved complete remission
(78%). At a median follow-up of 45 months the overall
survival was 56% (95% c.i. 32–79%) and the loco-regional
control 71% (95% c.i. 52–91%). Toxicity involved re-
versible renal insufficiency of ≥ grade II in 9 patients (39%)
and neutropenic fever in 9 patients (39%). All patients
suffered from moderate to severe mucositis (grade II/III),
and 19 patients presented cutaneous toxicity grade III. Con-
comitant boost-accelerated RT combined with concurrent
full-dose cisplatin/5-FU chemotherapy and amifostine is
feasible with manageable, although substantial, toxicity.
The overall survival of 4 years is promising. Newer regi-
mens causing less acute mucosal and skin toxicity are
needed.
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Introduction
Most patients with squamous cell carcinoma of the head
and neck (SCCHN) present in a locoregionally advanced
stage. Because of heavy exposure to alcohol and tobacco,
many patients also suffer from chronic heart, lung and
liver diseases, limiting treatment possibilities. Despite
surgery and/or radiotherapy (RT), most patients with ad-
vanced disease (stage III and IV) will experience recur-
rences both with local and distant metastases, and overall
survival for all causes remains poor [4, 8, 41, 47]. Fur-
thermore, radical surgery for advanced disease is often
mutilating, impairing organ function (speech, swallow-
ing) and leading to social isolation [14, 52]. Similarly, ra-
diochemotherapy may be associated with significant late
xerostomia and fibrosis, leading to nutritional difficulties
and affecting the quality of life. Conventional RT (com-
monly 2 Gy/fraction, 70 Gy over 7 weeks) for unresectable
disease is associated with a high locoregional failure rate.
Furthermore, patients with advanced nodal disease are at
high risk for distant metastases, and micrometastatic dis-
ease present at the time of diagnosis remains untreated by
RT or surgery [3, 8, 28].
Several advances have been made over the last decade.
New surgical techniques, e.g., microvascular free tissue
transfer, have allowed for less mutilating surgery, better
organ function and more rapid recovery. Alternative frac-
tionation schedules like concomitant boost-accelerated RT
or hyperfractionated RT have shown improved local con-
trol and survival in comparison [16, 37]. Shortening the
overall treatment time by accelerated fractionation will di-
minish the tumor cell repopulation in some tumors [18].
In the DAHANCA7 trial, treatment time was reduced by
increasing the number of fractions per week from five to
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six, maintaining the overall treatment dose. Early toxicity
was increased, but not late toxicity. Local control and sur-
vival were improved [34, 35].
Chemotherapy has consistently demonstrated responses
in previously untreated patients. However, despite response
rates exceeding 80%, neoadjuvant chemotherapy has failed
to improve overall survival in several randomized trials
[26, 36]. Nevertheless, patients treated with chemotherapy
have a much lower incidence of developing distant metas-
tases, and it may allow for organ preservation in two-
thirds of the patients with larynx and hypopharynx pri-
maries [25, 27, 38, 48, 51].
By giving chemotherapy simultaneously with radiation,
additional synergistic antitumoral activity may be gained.
Chemotherapy will not only act on tumor cells outside the
radiation field, but it will also induce additional cellular
damage, thus limiting the cells possibility for repair [13,
42, 46, 50]. Several randomized studies have shown an
improved outcome with concomitant chemoradiotherapy
[6, 9]. The main limitation of concomitant chemoradio-
therapy is increased acute toxicity, requiring frequent in-
terruptions of radiotherapy or significant dose reductions
in the chemotherapy. Prolonged breaks in radiotherapy and
a longer overall treatment time may allow for tumor re-
population and thus the loss of the gained additional ben-
efit, or it may even be detrimental [15, 18, 45]. Most con-
comitant chemoradiotherapy schemes administer only two
cycles of a single agent chemotherapy together with stan-
dard fractionation radiotherapy. This may not be sufficient
to control systemic disease and may reduce the incidence
of distant metastases.
The aim of our treatment scheme was to deliver three
cycles of a standard chemotherapy regimen together with
an accelerated radiotherapy. A secondary goal was also to
reduce the overall treatment time from diagnosis until the
end of all therapy by limiting the duration without any
therapy and beginning the first cycle of chemotherapy as
soon as possible after diagnosis, thus using the time needed
for RT planning and dental care for the administration of
an initial cycle of chemotherapy.
Subjects and methods
Twenty-three consecutive patients with advanced stage and histo-
logically confirmed squamous cell carcinoma of the head and neck
were treated at the University Hospital of Lausanne (CHUV). Eli-
gible patients had to have stage III or IV locally advanced disease;
three patients with stage II disease were included to prevent them
from having to undergo mutilating surgery (total glossectomy in
two patients with base of tongue primaries and pharyngolaryngec-
tomy with esophageal stripping in one patient with double pri-
maries in the hypopharynx and esophagus). Tumors were classi-
fied according to the 1997 TNM classification [49] (Table 1). Pre-
treatment evaluation included panendoscopy (oro-pharyngo-laryn-
goscopy, bronchoscopy and esophagoscopy) in all but three pa-
tients (two patients with tumors located in the rhinopharynx and
one patient with unknown primary and comorbidities not permit-
ting general anesthesia). Imaging studies included a CT scan and/
or MRI at the primary site and neck, a chest X-ray and a CT of the
chest and upper abdomen. A bone scan was performed in 16 pa-
tients (70%). Baseline laboratory studies included blood chemistry
(electrolytes, liver and kidney function tests) and a complete blood
count. All patients were seen and discussed at our multidiscipli-
nary tumor board, and the treatment recommendation was made
jointly by head and neck surgeons, radiation oncologists and med-
ical oncologists with advice from the nursing staff, nutritionists
and dentists. A port-a-cath (PAC) and percutaneous endoscopic
gastrostomy (PEG) was routinely placed before or at the beginning
of treatment in 19 and 21 out of the 23 patients, respectively. On
the basis of our previous experience on early nutritional interven-
tion, professional surveillance, advice and support were available
during the entire treatment period [39]. Assistance for smoking
and alcohol cessation was offered to all patients, including nicotine
patches as indicated.
Toxicity was graded according to the Common Toxicity Crite-
ria [11]. Response to treatment was defined as follows: complete
response as the disappearance of all clinically and radiologically
visible disease, partial response as a decrease of the product of the
two largest perpendicular diameters by ≥50% and stable disease
(non-response) as a decrease of <50% or an increase of <25%. Sur-
vival was calculated according to the Kaplan-Meier method from
the date of inclusion (tumor board decision) until the date of death
or last follow-up [23]. The 95% confidence intervals were calcu-
lated from standard errors (survival ±1.96 SE). Event-free survival
was calculated until progression, local recurrence or distant metas-
tases, death of any cause or development of a second primary. The
likelihood of local control without primary site surgery was con-
sidered censored at the time of patient death if no event had yet oc-
curred. In the calculation of the overall survival with primary site
preservation, only those patients who were alive with no primary
site resection and with no residual or recurrent disease present at
the primary site were considered censored. Patients with unknown
primary (3) and nasopharynx primary (2) were excluded from the
organ preservation analysis.
Patient characteristics are summarized in Table 2. There were
20 males and 3 women. The median age was 54 years (35–70 years).
At the initial evaluation, the nutritional state was within normal
limits in the majority of the patients [mean body mass index (BMI)
24.2 (normal: 18.5–24.9), range 18.7–32.3]. Primary tumor local-
ization was the hypopharynx in seven patients, the base of the
tongue in ten, the nasopharynx in two and unknown (with N3 neck
disease) in three. One patient had an upper esophageal tumor with
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Table 1 TNM classification
N0 N1 N2 N3
Tx – – 1 2
T2 3 1 3 –
T3 2 1 2 5
T4 1 1 1 –
Table 2 Patient and disease characteristics. * Includes one patient
with a second primary in the hypopharynx, t includes one patient
with a second primary in esophagus
No. of patients 23
Male: female 20:3
Median age (range) 54 (35–70 years)
Localization Rhinopharynx 2







posterior tracheal wall infiltration. Two patients had synchronous
double primaries: a T2 hypopharyngeal carcinoma with a T1-can-
cer in the upper third of the esophagus and a T2 oropharyngeal car-
cinoma with a T1 supraglottic tumor. Seventy percent (16 patients)
presented with stage IV and 13% (4 patients) with stage III dis-
ease. Three patients with stage II disease were also included, two
base of the tongue primaries and one with two synchronous tu-
mors. One patient had undergone a laser resection 1 year before in-
clusion in this study for a primary carcinoma in the oral cavity.
Our treatment concept called for a minimal delay by starting
with the first cycle of chemotherapy as soon as possible after diag-
nosis (median time 19 days, range 12–49), while dental care as
well as RT planning were still underway (Fig. 1). The second and
third cycles of CT were planned during weeks 1 and 4 of radiation.
CT consisted of cisplatin (100 mg/m2, day 1) and 5-fluorouracil
(1,000 mg/m2 per day for 5 days as a continuous infusion). Amifos-
tine (910 mg/m2) was administered immediately before cisplatin in
order to reduce acute and late toxicity [7, 10, 31, 40].
RT started together with the 1st day of the second CT cycle
(day 22). We chose a moderately accelerated RT according to the
DAHANCA 7 trial (70 Gy in 6 weeks) [34]. Six fractions (2 Gy
each) a week in a monofractionated setting from Monday to Thurs-
day and two fractions on Fridays (with an interval of 6 h between
the two fractions) were given. 3-D conformal RT planning was
used according to the ICRU 50 standards in all patients [22]. The
clinical target volume (CTV) included the primary tumor as well
as involved and regional lymph nodes (bilateral cervical and bilat-
eral supraclavicular nodes in most patients). The planning target
volume (PTV) included a 5-mm margin around the CTV in the
three dimensions. Patient immobilization was realized using indi-
vidualized thermoplastic immobilization masks in all patients. Ir-
radiation was delivered by a telecobalt unit or a linear accelerator
using photons (6 MV) and electrons. Intensity-modulated RT (IMRT)
was not used. The PTV was irradiated to a total dose of 50 Gy; the
concomitant boost volume which included the primary tumor and
involved nodes received a total dose of 70 Gy (second Friday dose
during the first 5 weeks, and 5×2 Gy during the last treatment week).
Patients were seen by a medical oncologist and ENT surgeon
weekly, and by a radiation oncologist during RT. Special advice
and attention were given by the nursing team to skin care, and oral
hygiene was enforced. Symptomatic treatment for mucositis (so-
dium bicarbonate) was offered and oral candidiasis promptly treated
by fluconazol.
After treatment completion and after 2 months, the patients were
reassessed at the neck and primary site by the same team. MRI, CT
scan and biopsies were performed as indicated. Salvage surgery
was performed if necessary. Patients were then followed by the
ENT surgeon and radiation oncologist every 2 months for 2 years.
At that time a panendoscopy was performed, and patients without
evidence of disease subsequently were followed up every 6 months.
Results
Twenty-three patients were enrolled and 21 patients (91%)
completed the therapy as planned. Median RT duration was
42 days (range 36–51). One patient died after the first CT
cycle because of cardiac failure. One patient progressed
rapidly during cycle 1, and subsequently received pallia-
tive treatment only. One patient received only two cycles
of CT because of acute toxicity (neutropenic fever, grade
III mucositis and dermatitis).
Toxicity
Overall, 64 cycles of CT were administered. In three pa-
tients cisplatin had to be substituted by carboplatin be-
cause of renal insufficiency. A dose reduction of cisplatin
was necessary in six patients for seven cycles (11%). The
administration of the third cycle was delayed in nine pa-
tients and omitted in one patient. The incidence and inten-
sity of acute toxicity increased over treatment time (Table 3).
Moderate and reversible renal insufficiency occurred in
nine patients: grade II in 15% of the CT cycles and grade
III in 3%. Neutropenic fever was observed in nine patients
(39%) and in 15% of the cycles. It was more common in
the evaluation period of cycle 2 and 3 (three and four pa-
tients, respectively) than during the initial CT cycle alone.
One patient died 28 days after the end of treatment as the
result of septicemia secondary to neutropenia.
All patients suffered from moderate to severe mucosi-
tis (grade II/III). Dermatitis at the end of treatment was
common: two patients had grade II and 19 patients grade
III. No surgical interventions were needed for sequelae.
The main complaint at follow-up visits was mild to mod-
erate (grade I/II) xerostomia in all patients.
Supportive care
The median weight change during therapy was –8.6% of
the initial weight (range +5.3 to –15.9%); six patients
(29%) had a weight loss of >10% (grade 2). Twenty pa-
tients used PEG tubes. One patient had massive bleeding
during the PEG placement and needed laparotomy for he-
mostasis. The median time of functional gastrostomy was
8.9 months. One patient had his PEG removed after 21 days
because of infection. Only five patients were using it for
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Fig. 1 Treatment concept. Dx diagnosis, RT radiotherapy, PAC port-
a-cath, PEG percutaneous endoscopic gastrostomy, fr fraction
Table 3 Acute toxicity. ULN upper limit of normal
Cycle 1 Cycle 2 Cycle 3 No. of 
patients
Neutropenic fever 1 4 4 9
Creatinine (>1.5× ULN) 2 5 4 9
Mucositis (grade 3) 1 6 21 21
Dermatitis (grade 3) 0 1 19 19
Weight loss (>10%) 0 1 6 6
more than 1 year. Prolonged hospitalization (more than 7 days
per CT cycle) because of toxicity or general health status
was necessary in 12 patients in order to improve support-
ive care measures.
Response and survival
At the end of the chemoradiotherapy, 18 patients achieved
complete remission (78%). One patient with partial remis-
sion in the neck was rendered disease free by surgery (neck
dissection), and one patient with a base of the tongue pri-
mary was salvaged by total glossectomy and neck dissec-
tion. Two primarily inoperable patients, both with unknown
primary and stage 4 disease, did not respond to therapy.
With a median follow-up time of 45 months (range
0.6–63.4), overall survival at 4 years was 56% (95% c.i.
32–79%) (Fig. 2). Local control at 4 years was 84% (67–
100%) and locoregional control 71% (95% c.i. 52–91%),
respectively (Fig. 3). The event-free survival at 4 years
was 50% (95% c.i. 26–75%), and the number of events
was ten. Four patients experienced recurrence. One patient
with an upper esophageal carcinoma had a local recur-
rence at 5 months; another local recurrence was observed
in a patient with a hypopharynx primary at 34 months. One
patient with a nasopharynx primary experienced recur-
rence in the neck after 11 months, and one patient with a
hypopharynx tumor developed lung metastases 16 months
after diagnosis. He was offered salvage treatment by fur-
ther chemotherapy and surgery and died of a second non-
small cell lung cancer primary 2 years later. The organ preser-
vation rate was calculated for the 18 patients with base of
the tongue, hypopharyngeal and upper esophageal pri-
maries, excluding patients with unknown primaries and
nasopharynx cancer. At 3 years, 13 out of 18 patients are
alive with the organ in place (72%). Two patients are still
depending on PEG tubes for nutritional supplementation.
Discussion
Our study shows that the concurrent administration of three
cycles of full dose chemotherapy with cisplatin and 5-FU
and concomitant boost-accelerated RT of 70 Gy is feasible
in patients with advanced squamous cell carcinoma of the
head and neck. Nevertheless, the acute toxicity of this reg-
imen is substantial and requires close follow-up and sup-
portive care by an experienced multidisciplinary team.
Great emphasis was given to specialized and close nurs-
ing care, particularly in this group of patients known for
frequent non-compliance. The main chemotherapy-induced
toxicities were myelosuppression with neutropenic fever
and renal insufficiency. Virtually all patients developed mod-
erate to severe mucositis and dermatitis. However, with
careful local care and nutrition via a nasograstic tube or
PEG, the toxicity was manageable. In a similar study, Giralt
et al. reported 59% severe (≥ grade 3) mucositis and 14%
severe skin reactions [17]. Despite their less intensive ra-
diation regimen (60 Gy over 6.5 weeks, 1.8 Gy per frac-
tion), acute toxicity was still substantial. In a randomized
multicenter trial with hyperfractionated radiotherapy with
and without concomitant cisplatin/5-FU at reduced doses,
the incidence of severe mucositis was 77% in both groups,
with an additional 22% of patients experiencing patchy
(grade 2) mucositis [6]. A feeding tube was placed in 44
and 29% of patients with or without concomitant chemo-
therapy, respectively. Concomitant boost radiotherapy has
been shown to improve locoregional control and is con-
sidered the standard irradiation scheme by the RTOG
[16]. In their randomized trial, 86% of patients experi-
enced grade 2 or 3 mucosal toxicity.
In our study less than 30% of the patients had at most
a grade 2 weight loss of 10 to maximally 16%. Some pa-
tients even gained weight during therapy. In comparison,
Adelstein et al. administered two cycles of cisplatin/5-FU
together with standard fractionated definitive RT. In this
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Fig. 2 Overall survival
Fig. 3 Loco-regional control
randomized study, comparing radiochemotherapy with ra-
diation alone, feeding tubes were only placed as needed.
Thirty percent of the patients in the RT-only group and
58% of the patients in the radiochemotherapy group re-
quired a feeding tube. Despite this, the mean weight loss
was 6 and 12%, respectively, with 70% of patients having
a weight loss of >10% in the radiochemotherapy group [1,
2]. Our policy of placing a feeding tube prophylactically
together with ongoing counseling by a dietician may be
the key to avoid malnutrition during treatment [39].
With the aim of reducing acute hematological toxicity,
every chemotherapy cycle was preceded by a single dose
of amifostine [10, 24]. The contribution of only three ami-
fostine doses cannot be assessed in this study, but appears
to be of limited value. Administration of a lower dose of
amifostine daily before RT has shown a modest decrease
in the occurrence of late xerostomia; however, reduction
of mucositis could only be demonstrated in a subgroup of
patients with large radiation fields [5, 7]. Daily adminis-
tration of i.v. amifostine before radiotherapy is costly, la-
borious and associated with nausea and occasional hypo-
tension. Although a decrease in xerostomia has been shown
[7], the efficacy of amifostine in reducing the incidence or
severity of treatment-induced mucositis remains to be
demonstrated in a prospective randomized trial.
All but one patient received three cycles of chemother-
apy, although the third cycle had to be delayed or dose re-
duced in about half of the patients. No detrimental delays
in radiation treatment due to toxicity were necessary in
our study, while, despite a more gentle RT schedule, 42%
of patients required a temporary interruption of RT in the
study reported by Giralt [17].
Organ preservation with combined chemotherapy and
radiation has been shown for larynx and hypopharynx
cancer [27, 48]. In our study, we included ten patients with
advanced base of tongue cancers, for which a surgical ap-
proach would have required total glossectomy. Only one
of these patients subsequently required salvage surgery, and
one is depending on the PEG for nutrition after 45 months.
The other eight patients with base of tongue primaries
have good organ function (voice and swallowing).
Concomitant chemoradiotherapy has been shown to be
superior to radiotherapy alone in randomized trials. A meta-
analysis suggests an absolute benefit of 8% with concomi-
tant chemoradiotherapy [38]. In most studies, the chemo-
therapy dose has been reduced, and only one or two cy-
cles were administered. Similarly, hyperfractionated and
accelerated radiotherapy improved local control and sur-
vival in some randomized studies [16, 20, 21, 30, 43].
Two randomized studies compared hyperfractionated ra-
diotherapy with the same RT and concomitant cisplatin/5-
FU chemotherapy and showed an improvement in local
control and survival in the combined arm [6, 53]. How-
ever, in one of the trials RT was given with planned treat-
ment breaks during weeks 3 and 6 and in the other trial the
chemotherapy was given at a considerably lower dose and
with a longer interval between the treatment cycles. Com-
pared with conventional RT alone, alternating chemora-
diotherapy proved to be superior with a 5-year overall sur-
vival of 24% compared to 10% for conventional RT in a
study by Merlano [32, 33]. However, other studies did not
demonstrate an improvement in survival when alternating
chemoradiotherapy was compared to accelerated RT [12,
29]. In our study, accelerated concomitant boost radiation
therapy was administered without additional breaks other
than planned treatment-free days on weekends, and che-
motherapy cycles could be delivered at the standard 21–
28-day intervals.
All of our patients presented with advanced disease, and
surgical treatment would have been mutilating and would
have impaired organ function. In this group of patients
with poor prognosis, an overall survival of 56% at almost
4 years of follow-up is encouraging. Recurrences after
more than 3 years are rare in this disease, and these pa-
tients can be considered cured from their primary tumor.
It is of note that all the patients included in this protocol
did not qualify for randomized multicenter cooperative
group protocols because of the advanced stage, tumor lo-
calization or primary inoperability of their disease and
thus represent a group of patients with particularly poor
prognosis.
The concept of beginning chemotherapy immediately
after diagnosis while radiotherapy planning is still under-
way, followed by definitive accelerated chemoradiother-
apy, should be further explored. Although induction che-
motherapy has not been shown to improve survival in
many randomized trials [19, 44, 48], the early introduc-
tion of therapy and the reduction of tumor volume before
RT without prolonging overall treatment time may im-
prove the outcome. Experienced multidisciplinary teams
should deliver this type of therapy, and careful attention to
supportive care measures is required. Despite a growing
body of evidence for improved survival with concomitant
chemoradiotherapy, acute toxicity remains the main ob-
stacle for the wide acceptance of this treatment modality.
New treatment regimens with less toxicity (i.e., IMRT)
are warranted.
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